This triple mechanism is designed to address appetite suppression, energy expenditure, and glucagon secretion in parallel, producing a more comprehensive effect on cellular metabolism than either predecessor
Average 28.7% body weight loss at 68 weeks at the 12 mg dose (about 71.2 lbs / 32.3 kg average loss)
And experts warn that the GLP-1 treatment process can be different for everyone
A., Mocan, A., Echeverra, J., Pop, R
Amplitude O (Effect of Efpeglenatide on Cardiovascular Outcomes) revealed that patients with type 2 DM and CVD or kidney disease receiving once weekly efpeglenatide had a 27% lower incidence of the primary composite outcome and 32% lower risk of a composite renal outcome event compared to those receiving placebo [17]
Ideal candidates understand that oral semaglutide is not a cosmetic or temporary solution but a tool for managing a chronic metabolic condition